Dr CJ Wang, CEO of Frontier Biotech, shares his exciting ten-year journey with Frontier and their distinctive focus on HIV drug development, with their flagship compound, Aikening®, launched in China in 2018; their ongoing efforts to develop more novel therapeutics; their ambitious internationalization strategy to bring their therapies to patients globally; and their imminent plans to IPO!
Whether you look at it from a socioeconomic or personal perspective, HIV is a hugely significant therapeutic area with highly unmet medical needs.
